Phase 1 Study of Tomivosertib in Relapsed/Refractory AML Initiates Dose Finding
A Phase 1 trial for tomivosertib in relapsed or refractory acute myeloid leukemia is set to begin, utilizing Bayesian optimal interval dose finding design.
Phase I
Hematology / Acute Myeloid Leukemia
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The initiation of the Phase 1 trial for tomivosertib in relapsed or refractory AML is significant as it may introduce a new competitive treatment option in a challenging therapeutic area. Monitoring the trial's progress is essential for understanding its potential impact on market dynamics and positioning against existing therapies.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include the completion of the dose finding phase and the determination of the recommended starting dose for combination therapies.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.